TMC announces entrepreneurs, researchers joining its 2 health tech accelerators

coming soon

This month, TMCi is welcoming a slew of health tech and cancer innovators who will advance solutions in medicine over the next several months. Image via TMC.edu

The Texas Medical Center has announced the latest cohorts of its two health tech accelerators.

The Texas Medical Center Innovation has named eight companies that are in the Spring 2023 Accelerator for HealthTech cohort. TMCi also announced 21 participants are set to join the 2023 Accelerator for Cancer Therapeutics cohort. Both programs connect the entrepreneurs and innovators to experts at TMC’s campuses to solve unmet clinical needs and reach the next business milestone.

“At TMC Innovation, we start with a promise of uniting cutting-edge innovators in science and medicine with the talent found at the Texas Medical Center," says Emily Reiser, associate director of TMC Innovation, in a news release. "Our 2023 cohort members are tackling some of the most critical issues we face today in healthcare.

"We are excited to welcome a new group of researchers and companies to the TMC Innovation Factory, and to work collaboratively with our new cohort members and our partners from across the Texas Medical Center," she continues.

Here's what 2023 can expect from these two program's cohorts.

TMCi HealthTech Accelerator

The six-month, twice annual HealthTech Accelerator — originally launched in 2014 with over 225 alumni companies — focuses on digital health and medical device startups. The spring cohort are addressing solutions across maternal medicine, mental health, diagnostics, patient experience, and artificial intelligence.

"Uniting talented professionals from across the globe provides a unique opportunity for innovation, creativity, and development in diverse areas of expertise," says Devin Dunn, head of the Accelerator for Healthtech at TMCi, in the release. "Our tailored program maximizes participants' experiences while determining the best match between these companies and Texas Medical Center’s network."

The cohort was selected following a November bootcamp that introduced potential startup members to the TMC and the Houston health care community.

The following companies will join the TMC this month:

Based in Roseville, Minneapolis, Bloom Standard is deploying the first self-driving pediatric ultrasound to earlier diagnose heart and lung conditions in primary care, remote and under-resourced settings.
San Francisco-based Ejenta automates remote monitoring and care using AI technology exclusively licensed from NASA. “Intelligent agents” learn from connected devices, claims and EMR data to monitor patients, predict health and to provide automated support for patients and automated workflow for clinicians.
Kintsugi, based in Berkley, California, is on a mission to see mental health more clearly by developing novel voice biomarker infrastructure to detect signs of depression and anxiety from short clips of free-form speech.
San Francisco-based Lana Health is modernizing patient experiences, across the care continuum with an end-to-end, scalable platform, enabling frictionless care transitions, high patient satisfaction, and better clinical outcomes.
Liberate Medical, from Crestwood, Kentucky, improves outcomes for mechanically ventilated patients using its breakthrough, non-invasive, respiratory muscle-protective, neurostimulation device, VentFree.
Limbix, headquartered in Palo Alto, has a mission to improve mental health with accessible technology.
Nua Surgical, from Galway, Ireland, Nua Surgical is an award-winning Irish start-up dedicated to innovating in women’s health.
Houston-based Prana Thoracic is developing solutions for the detection and intervention of early-stage lung cancer.

Accelerator for Cancer Therapeutics

The TMC has announced the 21 researchers and companies tapped to join the 2023 Accelerator for Cancer Therapeutics.

The nine-month program, funded by the Cancer Prevention and Research Institute of Texas in partnership with the Gulf Coast Consortia and the University of Texas Medical Branch, supports investigators and early-stage biotechnology companies with innovative solutions in cancer therapeutics. Participants will be mentored by a group of scientific, business, and innovation leaders to ultimately be positioned to apply for grants and pitch to investors and corporate partners to further the development of their innovative cancer solutions.

“For this third cohort, we focused on a strategic and extensive recruitment process, including the evaluation of 1,679 cancer research projects. From 56 applications, we selected 21 participants that will gain access to valuable resources, integrated training and mentorship to prepare for clinical trials,” says Ahmed AlRawi, program manager of Accelerator for Cancer Therapeutics, in the release. “Our 2023 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. We are excited to continue the momentum and build off the successes of our previous years.”

Forty-five participants have gone through the accelerator program since its launch in 2021, and collectively, the entrepreneurs have raised more than $90 million in funding and three projects are in the clinic.

The 2023 cohort participants are focused on a wide range of therapeutic assets, including small molecule, antibody, peptide/protein, cell therapy, and other. The 2023 cohort kicks off their nine-month program in January.

The participants include:

Dr. Amit K. Tripathi – UNT-Health Science Center
Dr. Darshan Gandhi (ImproveBio, LLC)
Dr. Frank McKeon (Tract Pharmaceutical) – University of Houston
Dr. Hemanta Baruah (Aakha Biologics)
Dr. Joshua Gruber – UT-Southwestern
Dr. Kyoji Tsuchikama – UT Health Science Center-Houston
Dr. Maralice Conacci Sorrell – UT-Southwestern
Dr. Michael Buszczak – UT-Southwestern
Dr. Nadezhda (Nadia) German -Texas Tech-Lubbock
Dr. Parsa Modareszadeh (HemePro Therapeutics) – UT-Dallas
Dr. Robert Kruse (HydroGene Therapeutics)
Dr. Xiang Zhang – Baylor College of Medicine
Dr. Youngwook Won (Singular Immune, Inc.)
Dr. Zhi-Ping Liu (Raphael Pharmaceutical LLC) – UT-Southwestern
Dr. Jonathan Arambula (InnovoTEX Inc.)
Dr. Isaac Chan – UT-Southwestern
Dr. Olga Granaturova (Ruptakine Inc.) – UT Health Science Center-Houston
Dr. Jim Song (Tranquility Biodesign) – Texas A&M-College Station
Dr. Rosa Selenia Guerra-Resendez (Quetzal Bio, LLC) – Rice University
Dr. Cassian Yee (Mongoose Bio, LLC) – UT-MD Anderson Cancer Center
Dr. Manjeet Rao (Niragen, Inc.) – UT Health Science Center-San Antonio

From Your Site Articles

These nine companies are headed to Houston. Photo courtesy of TMC

TMC Innovation names 9 companies to its latest bootcamp

coming soon to Hou

Nine startups hailing from as far away as Sydney, Australia, are en route to Houston to participate in a week-long program at the Texas Medical Center's Innovation Factory.

The 2022 TMCi Accelerator for HealthTech Bootcamp is looking to accelerate these startups, which specialize in health tech innovation across the spectrum — maternal medicine, mental health, diagnostics, patient experience, and artificial intelligence.

“One of the things I love about Bootcamp is the opportunity to showcase the diversity of innovation our ecosystem attracts," says Devin Dunn, head of the Accelerator for Healthtech, in a news release. "The breadth of clinical and operational expertise in our Medical Campus creates a unique learning ground, truly unmatched. Our tailored accelerator program allows for an experience that is personalized to each company’s stage, specialty and growth objectives.”

After the week at TMC, a smaller group of startups will be accepted into the TMCi Accelerator, a six-month program focused on maturing strategic relationships.

“Startup companies who are impacting the future of healthcare need clinical evidence to validate their value proposition and grow their businesses," says Emily Reiser, associate director of TMC Innovation, in the release. "Our platform at the TMC sources the best talent from around the world, performs rigorous diligence, and brings entrepreneurs together with our dedicated network to drive value for each stakeholder. We are seeing this value proposition resonate with entrepreneurs, including international companies preparing to enter the US market”

The nine startups that will be participating in the program, per the news release, include:

Based in Roseville, Minneapolis, Bloom Standard is deploying the first self-driving pediatric ultrasound to earlier diagnose heart and lung conditions in primary care, remote and under-resourced settings.
Echo IQ, headquartered in Sydney, is a screening program that applies a proprietary algorithm to produce risk assessments for patients using their echocardiographic measurements.
San Francisco-based Ejenta automates remote monitoring and care using AI technology exclusively licensed from NASA. “Intelligent agents” learn from connected devices, claims and EMR data to monitor patients, predict health and to provide automated support for patients and automated workflow for clinicians.
Kintsugi, based in Berkley, California, is on a mission to see mental health more clearly by developing novel voice biomarker infrastructure to detect signs of depression and anxiety from short clips of free-form speech.
San Francisco-based Lana Health is modernizing patient experiences, across the care continuum with an end-to-end, scalable platform, enabling frictionless care transitions, high patient satisfaction, and better clinical outcomes.
Liberate Medical, from Crestwood, Kentucky, improves outcomes for mechanically ventilated patients using its breakthrough, non-invasive, respiratory muscle-protective, neurostimulation device, VentFree.
Limbix, headquartered in Palo Alto, has a mission to improve mental health with accessible technology.
Nua Surgical, from Galway, Ireland, Nua Surgical is an award-winning Irish start-up dedicated to innovating in women’s health.
Houston-based Prana Thoracic is developing solutions for the detection and intervention of early-stage lung cancer.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas improves ranking on annual report of most innovative states

moving up

Texas ranks above average — but outside the top 10 — in a new index that ranks the most innovative states.

To come up with its Most and Least Innovative States ranking, personal finance website WalletHub looked at 25 key indicators of innovation for the 50 states and the District of Columbia. These include a state’s share of STEM professionals, research and development spending per capita, and the proliferation of tech companies.

With an innovation score of 48.96 out of 100, Texas lands at No. 13 on the list. The District of Columbia stands atop the list, with an innovation score of 69.79, followed by Massachusetts, California, Colorado, and Washington.

Texas has steadily inched up the list — the state was No. 14 on the list in 2024 and has climbed up one spot each year since 2021.

Two components make up each state’s score: human capital and “innovation environment.” Texas ranks 14th in the human capital category and 13th in the innovation environment category.

“The most innovative states are especially attractive to people who have majored in science, technology, engineering and math, or STEM, as they offer abundant career opportunities and investment dollars, both for jobs at existing companies and for startups,” says WalletHub analyst Chip Lupo. “These states also instill young students with the skills they need to succeed in the current workforce, skills which are useful whether or not they pursue a STEM career.”

Despite not placing in the top 10 of the WalletHub index, Texas continues to produce thousands of jobs.

Citing data from the U.S. Bureau of Labor Statistics, Gov. Greg Abbott says Texas added the most nonfarm jobs in January (27,900) of any state and the most nonfarm jobs from January 2024 to January 2025 (187,700).

“Texas is America’s jobs engine, adding more new jobs in the last year than any other state,” Abbot said in a news release. “Our skilled and growing workforce and our business-friendly climate attract job-creating businesses in diverse industries from across the country and around the world. … Texas continues to remove regulatory red tape and invest in education, innovation, and infrastructure as we build a stronger, more prosperous Texas than ever before.”

Houston researchers find AI provides fresh perspectives to everyday problems

houston voices

We all know ChatGPT has forever changed how we do business. It’s modified how we access information, compose content and analyze data. It’s revolutionized the future of work and education. And it has transformed the way we interact with technology.

Now, thanks to a recent paper by Jaeyeon (Jae) Chung (Rice Business), we also know it’s making us better problem solvers.

Key findings:

A recent study finds ChatGPT-generated ideas are deemed an average of 15% more creative than traditional methods.
ChatGPT enhances “incremental,” but not “radical,” innovation.
ChatGPT boosts creativity in tasks normally associated with human traits, like empathy-based challenges.

According to the study published in Nature Human Behavior by Chung and Byung Cheol Lee (University of Houston), ChatGPT enhances our problem-solving abilities, especially with everyday challenges. Whether coming up with gifts for your teenage niece or pondering what to do with an old tennis racquet, ChatGPT has a unique ability to generate creative ideas.

“Creative problem-solving often requires connecting different concepts in a cohesive way,” Chung says. “ChatGPT excels at this because it pulls from a vast range of data, enabling it to generate new combinations of ideas.”

Can ChatGPT Really Make Us More Creative?

Chung and Lee sought to answer a central question: Can ChatGPT help people think more creatively than traditional search engines? To answer this, they conducted five experiments.

Each experiment asked participants to generate ideas for solving challenges, such as how to repurpose household items. Depending on the experiment, participants were divided into one of two or three groups: one that used ChatGPT; one that used conventional web search tools (e.g., Google); and one that used no external tool at all. The resulting ideas were evaluated by both laypeople and business experts based on two critical aspects of creativity: originality and appropriateness (i.e., practicality).

In one standout experiment, participants were asked to come up with an idea for a dining table that doesn’t exist on the market. The ChatGPT group came up with suggestions like a “rotating table,” a “floating table” and even “a table that adjusts its height based on the dining experience.” According to both judges and experts, the ChatGPT group consistently delivered the most creative solutions.

On average, across all experiments, ideas generated with ChatGPT were rated 15% more creative than those produced by traditional methods. This was true even when tasks were specifically designed to require empathy or involved multiple constraints — tasks we typically assume humans might be better at performing.

However, Chung and Lee also found a caveat: While ChatGPT excels at generating ideas that are “incrementally” new — i.e., building on existing concepts — it struggles to produce “radically” new ideas that break from established patterns. “ChatGPT is an incredible tool for tweaking and improving existing ideas, but when it comes to disruptive innovation, humans still hold the upper hand,” Chung notes.

Charting the Next Steps in AI and Creativity

Chung and Lee’s paper opens the door to many exciting avenues for future study. For example, researchers could explore whether ChatGPT’s creative abilities extend to more complex, high-stakes problem-solving environments. Could AI be harnessed to develop groundbreaking solutions in fields like medicine, engineering or social policy? Understanding the nuances of the collaboration between humans and AI could shape the future of education, work and even (as many people fear) art.

For professionals in creative fields like product design or marketing, the study holds especially significant implications. The ability to rapidly generate fresh ideas can be a game-changer in industries where staying ahead of trends is vital. For now, take a second before you throw out that old tennis racquet. Ask ChatGPT for inspiration — you’ll be surprised at how many ideas it comes up with, and how quickly.

-----

This article originally appeared on Rice Business Wisdom. Based on research by Jaeyeon (Jae) Chung and Byung Cheol Lee (University of Houston). Lee and Chung, “An empirical investigation of the impact of ChatGPT on creativity.” Nature Human Behavior (2024): https://doi.org/10.1038/s41562-024-01953-1.

Rice, MD Anderson receive $1.5 million to further brain cancer research

fresh funding

Rice University chemist Han Xiao, who also serves as director of the university’s Synthesis X Center, and cancer biologist Dihua Yu of The University of Texas MD Anderson Cancer Center have received a three-year, $1.5 million grant from the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation.

The funding will allow them to continue their research on treating brain metastasis by overcoming the blood-brain barrier, or the BBB, according to a news release.

Brain metastasis is the leading form of brain cancer, with survival rates below 20 percent within a year of diagnosis, according to the National Library of Medicine. It commonly originates from breast, lung and melanoma cancers.

The BBB typically acts as a protective barrier for the brain. However, it prevents most drugs from being able to directly reach the brain. According to Rice, only 2 percent of FDA-approved small molecule drugs can penetrate the BBB, limiting treatment options.

Xiao and Yu’s approach to dealing with the BBB includes a light-induced brain delivery (LIBD) platform. The advanced system employs nanoparticles that are embedded with a near-infrared dye for the transport of therapeutic agents across the BBB. The research will evaluate the LIBD’s ability to improve the delivery of small-molecule drugs and biological therapies. Some therapies have shown potential for reducing cancer growth in laboratory studies, but they have struggled due to limited BBB penetration in animal models.

“Our LIBD platform represents a novel strategy for delivering drugs to the brain with precision and efficiency,” Xiao said in a news release. “This technology could not only improve outcomes for brain metastasis patients but also pave the way for treating other neurological diseases.”

The Kleberg Foundation looks for groundbreaking medical research proposals from leading institutions that focus on “innovative basic and applied biological research that advances scientific knowledge and human health” according to the foundation.

“This research is a testament to the power of collaboration and innovation,” Xiao said in a news release. “Together, we’re pushing the boundaries of what’s possible in treating brain metastasis and beyond.”

Rice launched the Synthesis X Center, or Synth X, last spring. It was born out of what started about eight years ago as informal meetings between Xiao's research group and others from the Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center. It aims to turn fundamental research into clinical applications through collaboration.

“This collaboration builds on the strengths of both research teams,” Xiao said in the release. “By combining SynthX Center's expertise in chemistry with Dr. Yu's expertise in cancer biology and brain metastases, we aim to create a transformative solution.”

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME